Bedia Jacob S, Delgado-Gonzalez Antonio, Huang Ying-Wen, Gonzalez Veronica D, Funingana Ionut-Gabriel, Rahil Zainab, Mike Alyssa, Lowber Alexis, Vias Maria, Ashworth Alan, Brenton James D, Fantl Wendy J
Department of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Department of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA; Baxter Laboratory for Stem Cell Biology, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Cell Rep Med. 2025 Sep 16;6(9):102295. doi: 10.1016/j.xcrm.2025.102295. Epub 2025 Aug 22.
Tubo-ovarian high-grade serous carcinoma (HGSC), the most lethal gynecologic malignancy, initially responds to platinum-based chemotherapy, but due to frequent defects in the DNA damage response (DDR), most tumors develop resistance. The molecular mechanisms underlying clinical platinum resistance remain poorly defined with no biomarkers or targeted therapies to improve outcomes. Here, applying mass cytometry, we quantify phosphorylation and abundance of DDR proteins in carboplatin-treated HGSC cell line models. Despite similar levels of intranuclear platinum, a proxy for carboplatin uptake, cells follow divergent fates, reflecting DDR heterogeneity. Unsupervised analysis reveals a continuum of DDR states, and matrix factorization identifies eight protein modules. The activity of one module, containing canonical DDR proteins, increases in carboplatin-sensitive cells. Resistant cells engage a broader DDR protein module. These findings demonstrate the ability of single-cell proteomics to identify functional DDR states and reveal a DDR sensitivity module as a promising biomarker for clinical stratification and therapeutic decisions in HGSC.